Peritransplantation vaccination with chaperone-rich cell lysate induces antileukemia immunity

Xinchun Chen, Yi - Zeng, Gang Li, Nicolas Larmonier, Michael W. Graner, Emmanuel Katsanis

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

We have reported that chaperone-rich cell lysate (CRCL) is an effective anticancer vaccine in immunocompetent mice. In this study, we explored the therapeutic applicability of CRCL in the context of syngeneic hematopoietic cell transplantation (HCT) to treat preexisting leukemia. Our results demonstrate that tumor growth is significantly delayed in mice receiving syngeneic HCT from 12B1 tumor CRCL-immunized donors compared with animals receiving HCT from nonimmunized donors. CRCL immunization after immune HCT further hindered tumor growth when compared with immune HCT without posttransplantation vaccination. The magnitude of the immune response was consistent with the antitumor effects observed in vivo. Rechallenge of surviving mice with 12B1 or A20 cells in opposite groins confirmed that mice had developed long-term tumor-specific immunity against 12B1 tumor cells. In addition, we documented that both T cells and natural killer cells contributed to the antitumor effect of CRCL vaccination, because depletion of either subset hampered tumor growth delay. Thus, our results indicate that CRCL is a promising vaccine capable of generating specific immune responses. This antitumor immunity can be effectively transferred to a host via HCT and further enhanced after HCT with additional tumor CRCL immunizations.

Original languageEnglish (US)
Pages (from-to)275-283
Number of pages9
JournalBiology of Blood and Marrow Transplantation
Volume12
Issue number3
DOIs
StatePublished - Mar 2006

Fingerprint

Cell Transplantation
Immunity
Vaccination
Neoplasms
Immunization
Vaccines
Growth
Groin
Natural Killer Cells
Leukemia
T-Lymphocytes

Keywords

  • BMT
  • Chaperone/heat shock proteins
  • CML

ASJC Scopus subject areas

  • Transplantation

Cite this

Peritransplantation vaccination with chaperone-rich cell lysate induces antileukemia immunity. / Chen, Xinchun; Zeng, Yi -; Li, Gang; Larmonier, Nicolas; Graner, Michael W.; Katsanis, Emmanuel.

In: Biology of Blood and Marrow Transplantation, Vol. 12, No. 3, 03.2006, p. 275-283.

Research output: Contribution to journalArticle

@article{8e770aa4dda14dfbb9df37fd3977659a,
title = "Peritransplantation vaccination with chaperone-rich cell lysate induces antileukemia immunity",
abstract = "We have reported that chaperone-rich cell lysate (CRCL) is an effective anticancer vaccine in immunocompetent mice. In this study, we explored the therapeutic applicability of CRCL in the context of syngeneic hematopoietic cell transplantation (HCT) to treat preexisting leukemia. Our results demonstrate that tumor growth is significantly delayed in mice receiving syngeneic HCT from 12B1 tumor CRCL-immunized donors compared with animals receiving HCT from nonimmunized donors. CRCL immunization after immune HCT further hindered tumor growth when compared with immune HCT without posttransplantation vaccination. The magnitude of the immune response was consistent with the antitumor effects observed in vivo. Rechallenge of surviving mice with 12B1 or A20 cells in opposite groins confirmed that mice had developed long-term tumor-specific immunity against 12B1 tumor cells. In addition, we documented that both T cells and natural killer cells contributed to the antitumor effect of CRCL vaccination, because depletion of either subset hampered tumor growth delay. Thus, our results indicate that CRCL is a promising vaccine capable of generating specific immune responses. This antitumor immunity can be effectively transferred to a host via HCT and further enhanced after HCT with additional tumor CRCL immunizations.",
keywords = "BMT, Chaperone/heat shock proteins, CML",
author = "Xinchun Chen and Zeng, {Yi -} and Gang Li and Nicolas Larmonier and Graner, {Michael W.} and Emmanuel Katsanis",
year = "2006",
month = "3",
doi = "10.1016/j.bbmt.2006.01.001",
language = "English (US)",
volume = "12",
pages = "275--283",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Peritransplantation vaccination with chaperone-rich cell lysate induces antileukemia immunity

AU - Chen, Xinchun

AU - Zeng, Yi -

AU - Li, Gang

AU - Larmonier, Nicolas

AU - Graner, Michael W.

AU - Katsanis, Emmanuel

PY - 2006/3

Y1 - 2006/3

N2 - We have reported that chaperone-rich cell lysate (CRCL) is an effective anticancer vaccine in immunocompetent mice. In this study, we explored the therapeutic applicability of CRCL in the context of syngeneic hematopoietic cell transplantation (HCT) to treat preexisting leukemia. Our results demonstrate that tumor growth is significantly delayed in mice receiving syngeneic HCT from 12B1 tumor CRCL-immunized donors compared with animals receiving HCT from nonimmunized donors. CRCL immunization after immune HCT further hindered tumor growth when compared with immune HCT without posttransplantation vaccination. The magnitude of the immune response was consistent with the antitumor effects observed in vivo. Rechallenge of surviving mice with 12B1 or A20 cells in opposite groins confirmed that mice had developed long-term tumor-specific immunity against 12B1 tumor cells. In addition, we documented that both T cells and natural killer cells contributed to the antitumor effect of CRCL vaccination, because depletion of either subset hampered tumor growth delay. Thus, our results indicate that CRCL is a promising vaccine capable of generating specific immune responses. This antitumor immunity can be effectively transferred to a host via HCT and further enhanced after HCT with additional tumor CRCL immunizations.

AB - We have reported that chaperone-rich cell lysate (CRCL) is an effective anticancer vaccine in immunocompetent mice. In this study, we explored the therapeutic applicability of CRCL in the context of syngeneic hematopoietic cell transplantation (HCT) to treat preexisting leukemia. Our results demonstrate that tumor growth is significantly delayed in mice receiving syngeneic HCT from 12B1 tumor CRCL-immunized donors compared with animals receiving HCT from nonimmunized donors. CRCL immunization after immune HCT further hindered tumor growth when compared with immune HCT without posttransplantation vaccination. The magnitude of the immune response was consistent with the antitumor effects observed in vivo. Rechallenge of surviving mice with 12B1 or A20 cells in opposite groins confirmed that mice had developed long-term tumor-specific immunity against 12B1 tumor cells. In addition, we documented that both T cells and natural killer cells contributed to the antitumor effect of CRCL vaccination, because depletion of either subset hampered tumor growth delay. Thus, our results indicate that CRCL is a promising vaccine capable of generating specific immune responses. This antitumor immunity can be effectively transferred to a host via HCT and further enhanced after HCT with additional tumor CRCL immunizations.

KW - BMT

KW - Chaperone/heat shock proteins

KW - CML

UR - http://www.scopus.com/inward/record.url?scp=33244463054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33244463054&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2006.01.001

DO - 10.1016/j.bbmt.2006.01.001

M3 - Article

C2 - 16503496

AN - SCOPUS:33244463054

VL - 12

SP - 275

EP - 283

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 3

ER -